Abdominal Aortic Aneurysm Infected by Yersinia pseudotuberculosis

Infected aneurysms caused by Yersinia are very uncommon and are principally due to Yersinia enterocolitica. We describe the first case of an infected aneurysm caused by Yersinia pseudotuberculosis in an elderly patient with a history of atherosclerotic cardiovascular disease

黃牛與荷蘭乳牛換毛期的研究

　　生物受到外在環境極大的影響，特別是身體表面，直接左右於外在環境的部分很多，與生理變化相同、形態上的變化也很顯著。覆蓋的毛髮掌管體溫調節與保護身體的功能，各種動物會依照品種，或者是個體，各自呈現著最適合各自生存環境的狀態。因此，熱帶地區的家畜與溫帶地區的家畜有所不同是極為理所當然的自然現象。與冷熱調節關係密切、依據季節轉變的覆蓋皮毛的換毛狀態亦是如此，不難想見溫帶地區的家畜、與熱帶地區的家畜身上顯現的差異性。本論文即為溫帶產乳牛Holstein與熱帶產牛的黃牛的換毛狀態比較調查。 　　研究內容如下所述。(1)換毛通常進行於春秋二季。不過，會因為品種的不同而有時期上的差異。Holstein在春天的5月開始換毛，秋天的話在10月以後才會開始。換毛最為明顯的時期是6月。黃牛的狀況是在春天的4月，秋天的9月開始換毛。4月中旬過後、以及9月底至10月初是換毛最為明顯的時期。這個換毛狀態也會因為不同個體而有些許的差異性。(2)除了春秋二季的定期換毛以外，每個月多少都會有一些換毛。將新生毛的比例加以平均的話，則可知Holstein在6月有34％，7月有12％，8月有31％的程度。黃牛則是在6月有12％，7月有16％，8月有26％這樣的程度。(3)只要換成夏毛的話，則其中不會混有冬毛。(4)覆蓋毛髮因應氣溫變化而有長度與粗細的不同，冬天細長，夏天粗短。(5) Holstein與黃牛互相比較，則換毛的顯著時期較遲。這是因為在因應氣候的方面，Holstein的反應程度比黃牛來得低。(6)一般而言，夏毛的生存期比冬毛短，夏毛在經過約略5個月之後轉為冬毛，而冬毛則是經過約略7個月後轉為夏毛。(7)髓質在夏天的時候不太發達。封面、書名頁、印記、目次頁 I　緒言 II　研究材料並ニ研究方法 　A）供試動物 　B）供試動物ノ飼養管理 　　i）黄牛ノ状態 　　ii）ホルスタインノ状態 　C）試驗期間及ビ採毛期日 　D）採毛方法 　E）調査方法 III　實驗結果 IV　實驗結果ノ觀察 　A）ホルスタイン 　B）黄牛 　C）ホルスタイント黄牛ノ比較 V　結論 VI　摘要 参【參】考文献 圖表 　（一） 　（二） 圖版、印記、封

Observatoires régionaux du pneumocoque : épidémiologie et résistance aux antibiotiques des souches de Streptococcus pneumoniae isolées en France en 2007

International audienceRésuméLes observatoires régionaux du pneumocoque (ORP), créés à partir de 1995, participent aux côtés du Centre national de référence des pneumocoques et de l’Institut de veille sanitaire à la surveillance étroite de l’évolution de la résistance du pneumocoque aux antibiotiques. En 2007, les 23 ORP français ont étudié la sensibilité aux antibiotiques et le sérogroupe de 5 302 souches de pneumocoque isolées de liquides céphalo-rachidiens (LCR), d’hémocultures, de pus d’otite moyenne aiguë, de liquides pleuraux de l’enfant et de l’adulte (≥ 16 ans) ainsi que de certains échantillons pulmonaires de l’adulte (≥ 16 ans). L’étude a montré que 38,2 % des souches étaient de sensibilité diminuée à la pénicilline (PSDP), 19,3 % à l’amoxicilline et 10,5 % au céfotaxime. Le pourcentage de PSDP différait selon les régions, allant de 29 % en Alsace à 50 % à Paris Ile-de-France Ouest. Il était plus élevé chez l’enfant (50,2 %) que chez l’adulte (33,7 %) et variait selon le prélèvement (enfant/adulte) : hémocultures (27,8 %/32,5 %), LCR (33,7 %/34,6 %), pus d’otite moyenne aiguë (60,2 %/27,5 %), liquides pleuraux (50 %/31 %). Les PSDP étaient souvent multirésistants avec en particulier un pourcentage élevé de résistance à l’érythromycine (84,2 % contre 12,7 % pour les pneumocoques sensibles à la pénicilline). Enfin, le sérogroupe majoritairement rencontré était le sérogroupe 19 (25,2 % des isolats).</p

Epidemiology and antimicrobial resistance of Streptococcus pneumoniae in France in 2007: data from the pneumococcus surveillance network.

International audienceAntimicrobial resistance of Streptococcus pneumoniae in France is closely monitored by the pneumococcus surveillance network, founded in 1995, which collects data from regional observatories (Observatoire Régionaux du Pneumocoque [ORP]). In 2007, 23 ORPs analyzed the antibiotic susceptibility of 5,302 isolates of S. pneumoniae recovered in France from cerebrospinal fluid, blood, middle ear fluid, and pleural fluid, as well as from adult respiratory samples. The study showed that 38.2% of the strains were nonsusceptible to penicillin, 19.3% nonsusceptible to amoxicillin, and 10.5% nonsusceptible to cefotaxime. The percentage of pneumococcus nonsusceptible to penicillin varied according to both the sample and the age of the patient (child/adult): blood (27.8%/32.5%), cerebrospinal fluid (33.7%/34.6%), middle ear fluid (60.2%/27.5%), and pleural fluid (50.0%/31.0%). Between 2003 and 2007, the frequency of penicillin resistance in invasive pneumococcal disease gradually decreased from 46.4% to 29.0% in children and from 43.8% to 32.7% in adults. This decrease coincided with the introduction of a seven-valent pneumococcal conjugate vaccine into immunization programs and with a general reduction in levels of antibiotic consumption in France

Persistent headaches one year after bacterial meningitis: prevalence, determinants and impact on quality of life

International audienceBackground: Little is known on headaches long-term persistence after bacterial meningitis and on their impact on patients' quality of life.Methods: In an ancillary study of the French national prospective cohort of community-acquired bacterial meningitis in adults (COMBAT) conducted between February 2013 and July 2015, we collected self-reported headaches before, at onset, and 12 months (M12) after meningitis. Determinants of persistent headache (PH) at M12, their association with M12 quality of life (SF 12), depression (Center for Epidemiologic Studies Depression Scale) and neuro-functional disability were analysed.Results: Among the 277 alive patients at M12 87/274 (31.8%), 213/271 (78.6%) and 86/277 (31.0%) reported headaches before, at the onset, and at M12, respectively. In multivariate analysis, female sex (OR: 2.75 [1.54-4.90]; p < 0.001), pre-existing headaches before meningitis (OR: 2.38 [1.32-4.30]; p < 0.01), higher neutrophilic polynuclei percentage in the CSF of the initial lumbar puncture (OR: 1.02 [1.00-1.04]; p < 0.05), and brain abscess during the initial hospitalisation (OR: 8.32 [1.97-35.16]; p < 0.01) were associated with M12 persistent headaches. Neither the responsible microorganism, nor the corticoids use were associated with M12 persistent headaches. M12 neuro-functional disability (altered Glasgow Outcome Scale; p < 0.01), M12 physical handicap (altered modified Rankin score; p < 0.001), M12 depressive symptoms (p < 0.0001), and M12 altered physical (p < 0.05) and mental (p < 0.0001) qualities of life were associated with M12 headaches.Conclusion: Persistent headaches are frequent one year after meningitis and are associated with quality of life alteration

One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study

Trial registration: ClinicalTrial.Gov identification number NCT01730690.International audienceIntroduction: COMBAT is a prospective, multicentre cohort study that enrolled consecutive adults with community-acquired bacterial meningitis (CABM) in 69 participating centres in France between February 2013 and July 2015 and followed them for 1 year.Methods: Patients aged at least 18 years old, hospitalised with CABM were followed during their hospitalisation and then contacted by phone 12 months after enrolment. Here we present the prevalence of sequelae at 12 months in a subgroup of patients with meningococcal meningitis.Results: Five of the 111 patients with meningococcal meningitis died during initial hospitalisation and two died between discharge and 12 months, leaving 104 patients alive 1 year after enrolment, 71 of whom provided 12-month follow-up data. The median age was 30.0 years and 54.1% of the patients had no identified risk factor for meningitis. More than 30% reported persistent headache, more than 40% were not satisfied with their sleep and 10% had concentration difficulties. Hearing loss was present in about 15% of the patients and more than 30% had depressive symptoms. About 13% of the patients with a previous professional activity had not resumed work. On the SF-12 Health Survey, almost 50% and 30% had physical component or mental component scores lower than the 25th percentile of the score distribution in the French general population. There was a non-significant improvement in the patients' disability scores from hospital discharge to 12 months (p = 0.16), but about 10% of the patients had residual disability.Conclusions: Although most patients in our cohort survive meningococcal meningitis, the long-term burden is substantial and therefore it is important to ensure a prolonged follow-up of survivors and to promote preventive strategies, including vaccination

Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease

International audienc